Navigation Links
Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
Date:2/26/2013

losing date of June 12, 2012 were $72.1 million.  Full year pro forma net sales of Erwinaze/Erwinase were $131.9 million.  2012 fourth quarter worldwide net sales of Erwinaze/Erwinase were $34.4 million.
  • Prialt® (ziconotide) intrathecal infusion:  2012 net sales of Prialt were $26.4 million, including $4.6 million related to a supply agreement to provide Prialt to Eisai Co. for distribution and sale in Europe recorded in the first quarter of 2012.  2012 fourth quarter net sales of Prialt were $5.9 million.
  • Psychiatry Products:  2012 net sales of the company's psychiatry products, including once-daily Luvox CR® (fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD, were $76.5 million.  2012 fourth quarter net sales of the psychiatry products were $18.0 million.
  • Other:  Net sales of other products for the full year and fourth quarter of 2012 were $26.9 million and $10.2 million, respectively.  "Other" includes products acquired in the EUSA Pharma and Azur Pharma transactions that are not mentioned above. 
  • Operating Expenses and Other Operating expenses for 2012 increased to $388.1 million compared to $144.4 million for 2011.  Operating expenses for the fourth quarter of 2012 increased to $116.3 million compared to $45.9 million for the same period of 2011.  Operating expenses increased over the prior year for the following reasons:

  • Cost of product sales for 2012 was $78.4 million compared to $13.9 million for 2011.  Cost of product sales for the fourth quarter of 2012 was $25.8 million compared to $3.9 million for the same period of 2011.  The increases in both periods were due primarily to higher net sales, with the full year 2012 cost of product sales also reflecting $16.8 million of acquisition accounting inventory fair value step-up adjustments.
  • Gross margin f
    '/>"/>

  • SOURCE Jazz Pharmaceuticals plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
    2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
    3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
    4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
    5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
    6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
    10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
    11. Avanir Pharmaceuticals To Present at Three Conferences In May
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... The Cadence Fitness & Health Center has been certified ... Association, a non-profit organization assisting medically integrated health and ... Fitness & Health Center is the only certified fitness ... Chicagoland area. "The certification means the Cadence ...
    (Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
    (Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
    Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
    ... YORK, May 24, 2011 Reportlinker.com ... report is available in its catalogue: ... (RVO) Therapeutics - Pipeline Assessment and ... http://www.reportlinker.com/p0511065/Retinal-Vein-Occlusion-RVO-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development ...
    ... May 24, 2011 Reportlinker.com announces that ... in its catalogue: Triple ... http://www.reportlinker.com/p0284984/Triple-Analysis-Lung-Cancer-Lymphoma-and-Angiogenesis.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... drug development strategies in both Lung Cancer ...
    Cached Medicine Technology:Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 2Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 3Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 4Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 5
    (Date:7/10/2014)... (PRWEB) July 10, 2014 Ivalua, ... latest results of the 4th “Trending in Procurement” ... model. , Every day multinational corporations process ... expense forms etc. To meet this challenge, more ... suites which can be defined as a suite ...
    (Date:7/10/2014)... 2014 (HealthDay News) -- Nature, not nurture, may play ... chimpanzees, a new study finds. "As is the ... cognitive [thinking] abilities in chimpanzees," William Hopkins of the ... a news release from the journal Current Biology ... the evolution of intelligence in humans, Hopkins, team said. ...
    (Date:7/10/2014)... who are sensitive to light or noise after a ... as anxiety and depression, a new study says. ... teens experience after concussion may help in planning for ... to return to play and what accommodations are needed ... and Dong Han, of the University of Kentucky in ...
    (Date:7/10/2014)... Dennis Thompson HealthDay Reporter ... Twitter wars that break out regularly between outspoken celebrities or ... your own relationship, a new study suggests. High amounts ... even if the couple is in a long-term relationship, according ... In turn, that friction can lead to cheating and ...
    (Date:7/10/2014)... Emergency Medical Service (EMS) responders felt better prepared to ... tactical training according to a new study in the ... the first study to specifically examine the EMS provider ... a shooter has not yet been neutralized or working ... such as the Columbine High School shooting, the Virginia ...
    Breaking Medicine News(10 mins):Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Some Teens May Face Emotional Problems After Concussion 2Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3Health News:Active shooter training increases comfort level of emergency responders 2
    ... ... study finds that generic drugs to be equally as effective as brand name drugs. ... (PRWEB) November 19, 2009 -- ... the fear many people have about generic drugs. A systematic review of 47 studies comparing ...
    ... ... Month and to promote nutritional education, diet delivery company Bistro MD is holding a ... enter. , ... November 19, 2009 -- In celebration of National Novel Writing Month and to promote ...
    ... ... allows users to perform feature based reverse engineering functions with new added functionality ... ... 2009 -- Creative Dezign Concepts Inc today announced that DezignWorks, a feature ...
    ... , BEIJING, Nov. 19 ... ), a leading China-based,medical device company that develops, manufactures and ... the second fiscal quarter ended September 30, 2009 ("2Q FY2009"). ... ("FY2009"). , , 2Q FY2009 Highlights, ...
    ... 18 The American Association of Homes and Services for ... on ensuring that the Community Living and Supportive Services (CLASS) ... Long-term services and supports are an essential part of health ... of reform. We are also grateful to Sen. Dodd (D-Conn.) ...
    ... , CHICAGO, Nov. 18 Smoking cigarettes not only contributes ... pain and spine problems, according to recent studies and observations ... encouraging Americans to "kick the habit" during the Nov. 19 ... the American Cancer Society. Throughout this month, Dr. Karahalios will ...
    Cached Medicine News:Health News:Generic Drugs Just as Effective as Brand Name Drugs Says DoctorSolve 2Health News:Diet Delivery Company Bistro MD Is Giving Away $1,500 in First Ever Creative Writing Contest 2Health News:Diet Delivery Company Bistro MD Is Giving Away $1,500 in First Ever Creative Writing Contest 3Health News:DezignWorks brings Intelligent Reverse Engineering capabilities to SolidWorks 2010 2Health News:DezignWorks brings Intelligent Reverse Engineering capabilities to SolidWorks 2010 3Health News:DezignWorks brings Intelligent Reverse Engineering capabilities to SolidWorks 2010 4Health News:DezignWorks brings Intelligent Reverse Engineering capabilities to SolidWorks 2010 5Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 2Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 3Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 4Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 5Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 6Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 7Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 8Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 9Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 10Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 11Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 12Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 13Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 14Health News:AAHSA Statement on Senate Health Reform Bill 2Health News:Smoking Contributes to Back Pain and Ineffective Surgical Treatments 2Health News:Smoking Contributes to Back Pain and Ineffective Surgical Treatments 3
    ... The ophthalmoscope with superior aspherical optics. ... illumination and observation beam by means of ... iris reflex (Gullstrand-principle). The Beta 200 allows ... illuminated section of the retina even with ...
    Our standard ophthalmoscopes feature halogen light for true tissue color and consistent, long-lasting illumination, and six apertures for general and specialist use....
    ... an innovative and patented new optical ... enabling technology makes it easier to ... dramatically wider, more panoramic view of ... ever before achieved with a standard ...
    The world's first automatic computation program analyzes massive amount of measurement data and computes "the most comfortable value" for the patient....
    Medicine Products: